Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BridgeBio Pharma Analyst Ratings and Price Targets | NASDAQ:BBIO | Benzinga
BridgeBio Pharma Inc has a consensus price target of $46.33 based on the ratings of 20 analysts. The high is $95 issued by Cantor Fitzgerald on February 21, 2025. The low is $19 issued by SVB Leerink on January 23, 2023. The 3 most-recent analyst ratings were released by JP Morgan, Citigroup, and Cantor Fitzgerald on March 24, 2025, February 21, 2025, and February 21, 2025, respectively. With an average price target of $64.67 between JP Morgan, Citigroup, and Cantor Fitzgerald, there's an implied 75.80% upside for BridgeBio Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Citigroup
Cantor Fitzgerald
Scotiabank
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for BridgeBio Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/24/2025 | Buy Now | 35.92% | JP Morgan | Anupam Rama60% | $44 → $50 | Maintains | Overweight | Get Alert |
| 02/21/2025 | Buy Now | 33.21% | Citigroup | David Lebowitz52% | $45 → $49 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 158.26% | Cantor Fitzgerald | Josh Schimmer55% | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
| 02/21/2025 | Buy Now | 41.36% | Scotiabank | Greg Harrison51% | $49 → $52 | Maintains | Sector Outperform | Get Alert |
| 02/13/2025 | Buy Now | 33.21% | HC Wainwright & Co. | Raghuram Selvaraju43% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 33.21% | Scotiabank | Greg Harrison51% | $48 → $49 | Maintains | Sector Outperform | Get Alert |
| 12/23/2024 | Buy Now | 35.92% | Evercore ISI Group | Cory Kasimov69% | $45 → $50 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | 33.21% | HC Wainwright & Co. | Raghuram Selvaraju43% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 30.49% | Scotiabank | Greg Harrison51% | $45 → $48 | Maintains | Sector Outperform | Get Alert |
| 11/25/2024 | Buy Now | 22.33% | B of A Securities | Geoff Meacham63% | $42 → $45 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 33.21% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $49 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 22.33% | Scotiabank | Greg Harrison51% | $44 → $45 | Maintains | Sector Outperform | Get Alert |
| 10/25/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 25.05% | Leerink Partners | Mani Foroohar46% | $47 → $46 | Maintains | Outperform | Get Alert |
| 10/16/2024 | Buy Now | 19.61% | Scotiabank | Greg Harrison51% | → $44 | Initiates | → Sector Outperform | Get Alert |
| 10/03/2024 | Buy Now | — | Oppenheimer | Leland Gershell70% | — | Initiates | → Perform | Get Alert |
| 10/02/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/30/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 90.29% | Cantor Fitzgerald | Josh Schimmer55% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 14.18% | B of A Securities | Geoff Meacham63% | $42 → $42 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 90.29% | Cantor Fitzgerald | Josh Schimmer55% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 25.05% | Piper Sandler | Biren Amin40% | → $46 | Initiates | → Overweight | Get Alert |
| 09/03/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/27/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 16.9% | JP Morgan | Anupam Rama60% | $46 → $43 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 22.33% | Evercore ISI Group | Cory Kasimov69% | $50 → $45 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 90.29% | Cantor Fitzgerald | Josh Schimmer55% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 06/25/2024 | Buy Now | 14.18% | B of A Securities | Geoff Meacham63% | $50 → $42 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 90.29% | Cantor Fitzgerald | Josh Schimmer55% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 05/28/2024 | Buy Now | 27.77% | UBS | Eliana Merle46% | $51 → $47 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 16.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $47 → $43 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 35.92% | Evercore ISI Group | Cory Kasimov69% | → $50 | Initiates | → Outperform | Get Alert |
| 03/20/2024 | Buy Now | 22.33% | JP Morgan | Anupam Rama60% | $35 → $45 | Maintains | Overweight | Get Alert |
| 03/19/2024 | Buy Now | 90.29% | Cantor Fitzgerald | Josh Schimmer55% | $60 → $70 | Maintains | Overweight | Get Alert |
| 03/11/2024 | Buy Now | 63.11% | Cantor Fitzgerald | Josh Schimmer55% | $50 → $60 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 44.08% | Mizuho | Salim Syed44% | $60 → $53 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 27.77% | HC Wainwright & Co. | Raghuram Selvaraju43% | $47 → $47 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 25.05% | Citigroup | David Lebowitz52% | $42 → $46 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 0.58% | BMO Capital | Kostas Biliouris34% | → $37 | Initiates | → Market Perform | Get Alert |
| 01/29/2024 | Buy Now | 27.77% | HC Wainwright & Co. | Raghuram Selvaraju43% | $22 → $47 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 35.92% | Cantor Fitzgerald | Josh Schimmer55% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 14.18% | Citigroup | David Lebowitz52% | → $42 | Initiates | → Buy | Get Alert |
| 10/24/2023 | Buy Now | 35.92% | Cantor Fitzgerald | Josh Schimmer55% | → $50 | Initiates | → Overweight | Get Alert |
| 08/28/2023 | Buy Now | 63.11% | Mizuho | Salim Syed44% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | 3.3% | JP Morgan | Anupam Rama60% | $42 → $38 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 63.11% | Mizuho | Salim Syed44% | $50 → $60 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 35.92% | Goldman Sachs | Paul Choi57% | $29 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 25.05% | Raymond James | Dane Leone45% | $29 → $46 | Maintains | Outperform | Get Alert |
| 07/18/2023 | Buy Now | -10.29% | Jefferies | Eun Yang34% | $24 → $33 | Downgrade | Buy → Hold | Get Alert |
| 05/08/2023 | Buy Now | -21.16% | Mizuho | Salim Syed44% | $23 → $29 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 8.74% | Evercore ISI Group | Josh Schimmer55% | → $40 | Initiates | → Outperform | Get Alert |
| 04/13/2023 | Buy Now | -26.6% | SVB Securities | Mani Foroohar46% | $25 → $27 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | -37.47% | JP Morgan | Anupam Rama60% | $18 → $23 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | -23.88% | Goldman Sachs | Paul Choi57% | $20 → $28 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | -21.16% | Raymond James | Dane Leone45% | $17 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren48% | — | Initiates | → Outperform | Get Alert |
| 01/23/2023 | Buy Now | -48.35% | SVB Leerink | Mani Foroohar46% | $23 → $19 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | -48.35% | JP Morgan | Anupam Rama60% | $20 → $19 | Maintains | Overweight | Get Alert |
| 08/24/2022 | Buy Now | -37.47% | Mizuho | Salim Syed44% | $25 → $23 | Maintains | Buy | Get Alert |
| 07/26/2022 | Buy Now | -18.45% | SVB Leerink | Mani Foroohar46% | $27 → $30 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -48.35% | Goldman Sachs | Paul Choi57% | $24 → $19 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | -26.6% | SVB Leerink | Mani Foroohar46% | $26 → $27 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for BridgeBio Pharma (BBIO) stock?
The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by JP Morgan on March 24, 2025. The analyst firm set a price target for $50.00 expecting BBIO to rise to within 12 months (a possible 35.92% upside). 39 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by JP Morgan, and BridgeBio Pharma maintained their overweight rating.
When was the last upgrade for BridgeBio Pharma (BBIO)?
There is no last upgrade for BridgeBio Pharma
When was the last downgrade for BridgeBio Pharma (BBIO)?
The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on March 24, 2025 so you should expect the next rating to be made available sometime around March 24, 2026.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $44.00 to $50.00. The current price BridgeBio Pharma (BBIO) is trading at is $36.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.